×
Back to Agenda
Critical Appraisal of Artificial Intelligence Solutions for Pharmacovigilance
Session Chair(s)
Jim W. Barrett, PHD, MSC
Senior Data Scientist, Uppsala Monitoring Centre (UMC), Sweden
Artificial intelligence solutions may support and enhance human decision-making and information processing throughout pharmacovigilance. This session aims to outline best practices and potential pitfalls in their use.
Learning Objective : Recognize key challenges in assessing artificial intelligence solutions and interpreting evaluations of their performance; Describe some best practices for critical appraisal of artificial intelligence solutions; Identify the need for consideration of human computer interactions.
Speaker(s)
Phil Tregunno
Deputy Director - Patient Safety Monitoring, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
MHRA Update
Monica Munoz, PHARMD, PHD
Division Director, Division of Pharmacovigilance-I, OSE, CDER, FDA, United States
FDA Update
Andrew Bate, PHD, MA
Vice President, Head of Safety Innovation and Analytics, GSK, United Kingdom
Industry Update
Have an account?